Dyne Therapeutics is a US-based biotech company that develops therapeutics for genetically driven muscle diseases. It focuses on myotonic dystrophy type 1, duchenne muscular dystrophy, facioscapulohumeral dystrophy, and rare skeletal muscle, cardiac, and metabolic muscle diseases. The company uses its FORCE platform to deliver disease-modifying therapeutics. Dyne Therapeutics was founded in 2017 and is headquartered in Waltham, Massachusetts.